1. GPCR/G Protein MAPK/ERK Pathway PI3K/Akt/mTOR Stem Cell/Wnt Protein Tyrosine Kinase/RTK
  2. Ras Akt ERK VEGFR
  3. NY0123

NY0123 是一种 EPAC1 抑制剂。NY0123 显著抑制 EPAC1、磷酸化 AKT、磷酸化 ERK1/2 和磷酸化 VEGFR2 的表达。NY0123 可抑制三阴性乳腺癌的血管生成与肿瘤生长。NY0123 可用于三阴性乳腺癌的相关研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

NY0123

NY0123 Chemical Structure

CAS No. : 1801911-70-5

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

查看 Ras 亚型特异性产品:

查看 Akt 亚型特异性产品:

查看 ERK 亚型特异性产品:

查看 VEGFR 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

NY0123 is a EPAC1 inhibitor. NY0123 significantly inhibits the expression of EPAC1, phosphorylated AKT, phosphorylated ERK1/2 and phosphorylated VEGFR2. NY0123 inhibits angiogenesis and tumor growth of triple-negative breast cancer. NY0123 is applicable to relevant research on triple-negative breast cancer[1].

IC50 & Target[1]

VEGFR2

 

ERK1

 

ERK2

 

EPAC1

 

体内研究
(In Vivo)

NY0123 (10 mg/kg;腹腔注射;每 2 天 1 次) 可显著抑制 BALB/c 小鼠体内三阴性乳腺癌的肿瘤生长、血管生成及细胞增殖,其疗效优于 ESI-09,且未观察到器官毒性[1]
NY0123 (25-100 μM;鸡胚尿囊膜局部给予;单次;孵育 48 h) 可显著抑制 Gallus gallus domesticus (家鸡) 胚胎尿囊膜模型中的血管生成,且效果优于 ESI-09[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 5-6 weeks old, 4T1 cell xenograft model)[1]
Dosage: 10 mg/kg
Administration: i.p.; every two days; 14 days
Result: Significantly reduced tumor volume and tumor weight compared to DMSO control.
Significantly lowered tumor microvessel density (measured via CD31 IHC staining) and tumor cell proliferation index (measured via Ki67 IHC staining) compared to DMSO control.
Exhibited greater inhibitory effects on tumor volume, tumor weight, MVD, and proliferation index than ESI-09.
Showed no treatment-related organ toxicities via H&E staining of heart, liver, lung, brain, spleen, kidney, and intestine tissues.
Animal Model: White leghorn (7-day-old embryo, CAM vascularization model)[1]
Dosage: 25 μM, 50 μM, 100 μM
Administration: topical application to CAM; single dose; 48-hour incubation
Result: Significantly reduced CAM microvessel density at 100 μM compared to DMSO control.
Exhibited greater inhibitory effects on angiogenesis at 100 μM than ESI-09 at the same concentration.
分子量

399.66

Formula

C16H13Cl3N4O2

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
NY0123
目录号:
HY-123795
需求量: